数据显示，诺安基金旗下1只基金位居益盛药业十大流通股东。诺安多策略混合A（320016）三季度新 进十大流通股东，持有股数198.63万股，占流通股的比例为0.86%。根据测算，今日浮亏损失约83.42万 元。连续4天下跌期间浮亏损失85.41万元。 11月21日，益盛药业跌5.12%，截至发稿，报7.79元/股，成交5162.70万元，换手率2.79%，总市值25.78 亿元。益盛药业股价已经连续4天下跌，区间累计跌幅4.98%。 资料显示，吉林省集安益盛药业股份有限公司位于吉林省集安市文化东路17-20号，成立日期1997年6月 11日，上市日期2011年3月18日，公司主营业务涉及中成药研发、生产、销售。主营业务收入构成为： 胶囊类产品47.89%，针剂类产品30.94%，化妆品7.39%，人参类产品6.89%，其他产品6.59%，蜂制品 0.31%。 从益盛药业十大流通股东角度 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 诺安多策略混合A（ ...

Core Viewpoint - Yisheng Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 23.66% but a recent decline of 2.12% over the past five trading days [1][2]. Financial Performance - For the period from January to September 2025, Yisheng Pharmaceutical reported a revenue of 476 million yuan, representing a year-on-year decrease of 5.81%. The net profit attributable to shareholders was 24.13 million yuan, down 32.72% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 213 million yuan, with 99.29 million yuan distributed over the past three years [3]. Shareholder Information - As of November 10, 2025, the number of shareholders for Yisheng Pharmaceutical was 19,700, a decrease of 1.92% from the previous period. The average number of circulating shares per person increased by 1.96% to 11,740 shares [2]. - Notably, as of September 30, 2025, the eighth largest circulating shareholder is the Nuoan Multi-Strategy Mixed A fund, which holds 1.9863 million shares as a new shareholder [3]. Stock Performance - As of November 19, Yisheng Pharmaceutical's stock price was 8.31 yuan per share, with a market capitalization of 2.75 billion yuan. The stock saw a trading volume of 12.1 million yuan and a turnover rate of 0.62% [1].